Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-09-12
2008-09-23
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S015800, C530S300000, C530S323000, C530S326000, C530S328000
Reexamination Certificate
active
07427590
ABSTRACT:
This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.
REFERENCES:
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6617156 (2003-09-01), Doucette-Stamm et al.
Rudinger, In.Peptide Hormones, J. A. Pazons, ed., University Park Press, Baltimore, 1976, pp. 1-7.
Bassan, M., et al., “Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide,”Journal of Neurochemistry, 1999, pp. 1283-1293, vol. 72, No. 3, Lippincott Williams & Wilkins, Inc., Philadelphia.
Brenneman, D., et al., “A Femtomolar-acting Neuroprotective Peptide,”The Journal of Clinical Investigation, May 1996, pp. 2299-2307, vol. 97, No. 10.
Brenneman, D., et al., “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides,”The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 619-627, vol. 285, No. 2, USA.
Glazner, G., et al., “Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development,”Anat Embryol, 1999, pp. 65-71, vol. 200, Springer-Verlag.
Gozes, I., et al., “Activity-Dependent Neurotrophic Factor (ADNF),”Journal of Molecular Neuroscience, 1996, pp. 235-244, vol. 7, Humana Press, Inc.
Gozes, I., et al., “Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity,”Developmental Brain Research, 1997, pp. 167-175, vol. 99, Elsevier Science B.V.
Brenneman Douglas E.
Castellon Raquel
Gozes Illana
Hauser Janet M.
Spong Catherine Y.
Gucker Stephen
Ramot at Tel-Aviv University Ltd.
Stucker Jeffrey
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Neurothrophic components of the ADNF I complex does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurothrophic components of the ADNF I complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurothrophic components of the ADNF I complex will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986055